AI, Sam Altman

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...
Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...
"Trump represents an unprecedented threat to America," Altman wrote in 2016. The day after President Donald Trump returned to office, Sam Altman, the CEO of tech giant OpenAI, stood behind the ...
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials this year ...
The price of Worldcoin jumped Wednesday, leading the crypto market after OpenAI's $500 billion AI initiative was unveiled.